prednisone

P4, N=450, Active, not recruiting, University of Turin, Italy | Recruiting --> Active, not recruiting

Her rheumatoid arthritis had been managed with upadacitinib for several years, which was discontinued due to persistent transaminitis...The rash resolved slowly in a month after discontinuation of tocilizumab and prescription of prednisone 20 mg daily. At her 3-month follow-up, the patient remained in remission, and her rheumatoid arthritis was uneventfully managed with abatacept. While most cases of biologic-associated LCV are induced by TNF-α inhibitors, only two known cases of tocilizumab-induced hypersensitivity vasculitis have been published in the literature. Our case represents only the third reported instance in the literature, highlighting the need to raise awareness of tocilizumab as a potential cause of leukocytoclastic vasculitis and the importance of prompt recognition and management.

P3, N=114, Enrolling by invitation, N.N. Petrov National Medical Research Center of Oncology

P1/2, N=145, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026

We present a case of a 59-year-old postmenopausal female with metastatic hormone receptor-positive breast cancer who started treatment with fulvestrant and ribociclib after progression on anastrozole...Ribociclib was held, and after no improvement in 28 days, she was treated with a 6-day course of prednisone 1 mg/kg, with significant improvement in her liver enzymes...Following normalization of her liver enzymes, she was rechallenged with abemaciclib with no recurrent hepatotoxicity. Ribociclib hepatotoxicity can be successfully treated with withdrawal of the medication and a short course of corticosteroids if liver enzymes do not improve following a 28-day withdrawal, highlighting a potential immune-mediated mechanism. Additionally, rechallenge with another cyclin-dependent kinase 4 and 6 inhibitor is a safe and effective strategy that should be considered.

The antibody-drug conjugate brentuximab vedotin (BV) has significantly improved outcomes for CD30-expressing lymphomas. The ECHELON-2 trial established BV combined with cyclophosphamide, doxorubicin, and prednisone (CHP) as a frontline standard for systemic anaplastic large cell lymphoma, demonstrating superior survival over the traditional CHOP regimen...We assess alternative strategies, such as BV-based combinations with immunotherapies or alternative chemotherapies, the integration of other targeted agents, and the transformative potential of advanced cellular treatments like anti-CD30 chimeric antigen receptor (CAR)-T cell therapy for relapsed/refractory disease. The collective evidence signals a paradigm shift from a one-size-fits-all approach toward personalized, precision-driven strategies aimed at maximizing efficacy, minimizing toxicity, and improving long-term quality of life for patients with CD30-positive lymphomas.

He was treated with R-CHOEP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone, and etoposide), which was later switched to R-CHOP (rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone) due to treatment-related neutropenia. The surgery was successful and there was no residual disease observed. This case highlights the diagnostic challenges of DLBCL presenting with isolated splenic infarction, emphasizing the role of PET/CT and biopsy in evaluation.

The condition remained poorly controlled despite administration of Prednisone combined with Hydroxychloroquine, and showed no significant improvement after adding methotrexate. reported here findings suggest that T-DXd may trigger multi-system involvement through immune-mediated mechanisms, resulting in drug-induced dermatomyositis and interstitial pneumonia. Our findings highlight the need for heightened vigilance regarding such immune-related adverse events during T-DXd therapy, where early recognition and intervention are critically important to avoid irreversible and possibly fatal complications.

P3, N=300, Recruiting, Staidson (Beijing) Biopharmaceuticals Co., Ltd | Not yet recruiting --> Recruiting

P=N/A, N=40, Completed, Massachusetts General Hospital | Active, not recruiting --> Completed

P3, N=504, Completed, Alliance Foundation Trials, LLC. | Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Jun 2025

She received granulocyte colony-stimulating factor (GCSF), thrombopoietin (TPO) mimetic, and immunosuppressive therapy with prednisone prior to primary cytoreductive surgery to no apparent gross residual disease...She was treated with anti-thymocyte globulin (ATG) and cyclosporine and subsequently received adjuvant chemotherapy with weekly cisplatin and subsequent addition of weekly paclitaxel, resulting in reduction in her serum Cancer Antigen-125 (CA-125) and no radiographic evidence of disease. Despite initial response, her clinical deterioration and her decision to forego further cancer- or aplastic anemia-directed therapy resulted in transition to home hospice care, and she was discharged 119 days after admission. This case report highlights the importance of multi-disciplinary collaboration to manage the medical complexities of paraneoplastic aplastic anemia secondary to a gynecologic malignancy.